Aducanumab: A Deep Dive into BIIB037 and its Impact A compound, originally known as BIIB037, represents a notable effort to combat mild Alzheimer's illness. Developed by Biogen, aducanumab acts by targeting amyloid https://violavhtm313152.blog5.net/93198968/text